IgA腎症におけるアタシセプトの有効性と安全性

基本情報

NCT ID: NCT02808429
ステータス: 中止
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 16
治験依頼者名: EMD Serono

概要

This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.

対象疾患

IgA Nephropathy

介入

Placebo(DRUG)

Atacicept 25 mg(DRUG)

Atacicept 75 mg(DRUG)

依頼者（Sponsor）

Emd Serono Research & Development Institute(INDUSTRY)

Merck Kgaa, Darmstadt, Germany(INDUSTRY)

実施施設 (1)

Juntendo University Hospital - Dept of Nephrology/Hypertension

Bunkyō City, Japan